Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PERIPHAGEN, INC. v. KRYSTAL BIOTECH, INC. et al
Case Number:
2:20-cv-00646
Court:
Nature of Suit:
Judge:
Firms
-
March 15, 2022
Pa. Bio Cos. End Gene Therapy Row In Deal Worth Up To $75M
Pittsburgh biotech company PeriphaGen Inc. reached a settlement to end litigation alleging its former lab partner, Krystal Biotech Inc., copied its gene therapy technology, with the deal worth at least $25 million and as high as $75 million, Krystal announced Monday.
-
May 04, 2020
Pa. Biotech Cos. Dispute Ownership Of Gene Therapy IP
Pittsburgh biotech company PeriphaGen Inc. is suing former lab partner Krystal Biotech Inc. in Pennsylvania federal court, claiming Krystal copied its gene therapy technology and used that to seek patents and investors.